Genetically engineering endothelial niche in human kidney organoids enables multilineage maturation, vascularization and de novo cell types

Maggiore, J.C., LeGraw, R., Przepiorski, A., Velazquez, J., Chaney, C., Streeter, E., Sliva-Barbaosa, A., Franks, J., Hislop, J., Hill, A., Wu, H., Pfister, K., Howden, S.E., Watkins, S., Little, M., Humphreys, B., Watson, A., Stolz, D., Kiani, S., Davidson, A.J., Carroll, T.J., Cleaver, O., Sims-Lucas, S., Ehrahimkhani, M., Hukriede, N.A.

BioRxiv doi: https://doi.org/10.1101/2023.05.30.542848

Vascularization plays a critical role in organ maturation and cell type development. Drug discovery, organ mimicry, and ultimately transplantation in a clinical setting thereby hinges on achieving robust vascularization of in vitro engineered organs. Here, focusing on human kidney organoids, we overcome this hurdle by combining an inducible ETS translocation variant 2 (ETV2) human induced pluripotent stem cell (iPSC) line, which directs endothelial fate, with a non-transgenic iPSC line in suspension organoid culture. The resulting human kidney organoids show extensive vascularization by endothelial cells with an identity most closely related to endogenous kidney endothelia. Vascularized organoids also show increased maturation of nephron structures including more mature podocytes with improved marker expression, foot process interdigitation, an associated fenestrated endothelium, and the presence of renin+ cells. The creation of an engineered vascular niche capable of improving kidney organoid maturation and cell type complexity is a significant step forward in the path to clinical translation. Furthermore, this approach is orthogonal to native tissue differentiation paths, hence readily adaptable to other organoid systems and thus has the potential for a broad impact on basic and translational organoid studies.

Date Published

Tuesday, March 19, 2019